Share Price:

APNASPENAspen Pharmacare Hldgs14323-151 (-1.04%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Our Stories

Our Stories

Aspen Australia participates in the 2026 APP Conference

The Australian Pharmacy Professional Conference & Trade Exhibition (APP) once again brought together nearly 8,000 pharmacy professionals from across Australia — pharmacists, interns, students, assistants, and industry partners — for three days filled with learning, networking, and professional development. This year’s event was especially memorable as Aspen Australia celebrated their 25-year anniversary.

Read More
Our Stories

Alphamed Work Journal Series

The Alphamed Work Journal series captures the insights, experiences, and reflections of Aspen Global Incorporated (AGI) colleagues participating in international upskilling programmes.

Read More
Our Stories

Stephen Saad on building Aspen

Stephen Saad joined Bronwyn Nielsen on Moneyweb TV’s flagship interview series, The Executive Exchange, to unpack his insightful and passionate leadership thinking, strategic decision‑making, and the forces influencing sustainable business growth in the challenging pharmaceutical sector in South Africa and internationally.

Read More
Our Stories

Aspen concludes an exclusive Women’s Health portfolio licensing agreement with Viramal

Aspen Pharma Ireland Limited (“Aspen”), a subsidiary of Aspen Pharmacare Holdings Limited, has entered into an exclusive licensing agreement (“Agreement”) with UK-based specialist pharmaceutical company Viramal Limited (“Viramal”) for an innovative Women’s Health portfolio. Under the agreement, Aspen will have exclusive rights to launch and commercialize selected products from Viramal’s portfolio in Europe, the Middle East, Brazil and Mexico.

Read More
Our Stories

A United Approach to Tackling Obesity

Obesity is far more than a medical condition — it is a complex societal challenge that affects individuals, families, communities, and the broader healthcare system in South Africa. Its growing prevalence is shaped by a mix of biological, environmental, and socioeconomic factors, making it an issue that cannot be addressed through personal effort alone.

Read More

Media Enquiries

Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com

Share on social

Follow on social

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: